跳转至内容
Merck
CN

R8883

利福平

powder, γ-irradiated

别名:

3-(4-甲基-1-哌嗪基亚胺甲基)利福霉素SV, 利米定, 甲哌利福霉素

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C43H58N4O12
化学文摘社编号:
分子量:
822.94
EC Number:
236-312-0
UNSPSC Code:
12352200
PubChem Substance ID:
Beilstein/REAXYS Number:
5723476
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

JQXXHWHPUNPDRT-WLSIYKJHSA-N

InChI

1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

SMILES string

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O

biological source

synthetic

sterility

γ-irradiated

form

powder

potency

≥880 μg per mg

color

orange to dark red

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria, mycobacteria

mode of action

protein synthesis | interferes

storage temp.

−20°C

正在寻找类似产品? 访问 产品对比指南

General description

Chemical structure: macrolide

Application

Rifampicin is used as an inhibitor of transcription initiation, blocking initiation of RNA synthesis.

Biochem/physiol Actions

作用方式:通过与RNA聚合酶的β-亚基结合抑制RNA合成的起始。
抑制DNA和蛋白质组装成成熟的病毒颗粒。

Packaging

150mg

Preparation Note

在小瓶中直接用甲醇制备储存液 (25mg/mL)。

Other Notes

Keep container tightly closed in a dry and well-ventilated place.Product is sensitive to light and moisture. Store under inert gas. Keep in a dry place.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sandra V Kik et al.
The Journal of infectious diseases, 211 Suppl 2, S58-S66 (2015-03-15)
The potential available market (PAM) for new diagnostics for tuberculosis that meet the specifications of the high-priority target product profiles (TPPs) is currently unknown. We estimated the PAM in 2020 in 4 high-burden countries (South Africa, Brazil, China, and India)
Toril Lindbäck et al.
Veterinary research, 41(1), 8-8 (2009-10-03)
Media-based bacteriological testing will fail to detect non-culturable organisms and the risk of consuming viable but non-culturable (VBNC) Listeria monocytogenes is unknown. We have here studied whether L. monocytogenes obtained from seafoods, processing environment and clinical cases enter the VBNC
Daniela Baldoni et al.
Antimicrobial agents and chemotherapy, 53(3), 1142-1148 (2008-12-17)
We investigated the activity of linezolid, alone and in combination with rifampin (rifampicin), against a methicillin-resistant Staphylococcus aureus (MRSA) strain in vitro and in a guinea pig model of foreign-body infection. The MIC, minimal bactericidal concentration (MBC) in logarithmic phase
Rodney Dawson et al.
Lancet (London, England), 385(9979), 1738-1747 (2015-03-22)
New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks
S Harbarth et al.
The Journal of antimicrobial chemotherapy, 70(1), 264-272 (2014-09-12)
The therapeutic arsenal for MRSA infections is limited. The aim of this study was to assess the non-inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the treatment of MRSA infection. We conducted a randomized, open-label, single-centre

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持